Clinical Trial Update: Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase I clinical trial evaluating Q702 in combination with azacitidine and venetoclax for relapsed or refractory acute myeloid leukemia is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Q702
• VIDAZA (AZACITIDINE)
• Venclyxto (Venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING